Want to join the conversation?
$MRK said that with more than 200 clinical trials and more than 100 combinations in over 30 tumor types, the company is seeing the potential to drive significant growth for KEYTRUDA longer term. In 2016, $MRK will continue to prioritize resources, focusing on JANUVIA, hospital acute care, vaccines and product launches such as ZEPATIER and KEYTRUDA.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!